Adrenocorticotropin- and cortisol-releasing effect of Hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 8, 1997, Pages 2439-2444

  Ghigo, E ^a   Arvat, E ^a   Ramunni, J ^a   Colao, A ^a,b   Gianotti, L ^a,b   Deghenghi, R ^a,c   Lombardi, G ^a   Camanni, F ^a,d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Ardana   (France)

^d MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXAPEPTIDE; HEXARELIN; HYDROCORTISONE; PROLACTIN; SOMATOMEDIN C;

ADOLESCENT; ADRENAL CORTEX ADENOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CUSHING SYNDROME; DRUG EFFECT; ECTOPIC CORTICOTROPIN PRODUCTION; FEMALE; FLUSHING; GROWTH HORMONE RELEASE; HORMONE ACTION; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SOMNOLENCE;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; CORTICOTROPIN-RELEASING HORMONE; CUSHING SYNDROME; FEMALE; GROWTH SUBSTANCES; HUMANS; HYDROCORTISONE; KINETICS; MALE; MIDDLE AGED; OLIGOPEPTIDES;

EID: 0030743911     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.8.2439     Document Type: Article

References (35)

1. Bowers CY, Veeraragavan K, Sethumadhavan K. 1993 Atypical growth hormone releasing peptides. In: Bercu BB, Walker RF, eds. Growth hormone. II. basic and clinical aspects. New York: Springer-Verlag; 203-222.
2. Ghigo E, Arvat E, Gianotti L, et al. 1996 Aging and GH-releasing peptides. In: Bercu B, Walker R, eds. Growth hormone secretagogues. New York: Serono Symposia; 415-431.
3. Deghenghi R. 1993 Growth hormone releasing peptides. In: Bercu B, Walker R, eds. Growth hormone secretagogues. New York: Serono Symposia; 85-102.
4. Korbonits M, Grossman AB. 1995 Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol Metab 6:43-49.
5. DeVita RJ, Wyratt MJ. 1996 Benzolactam growth hormone secretagogues. Drugs Future. 21:273-81.
6. Gertz BJ, Barrett JS, Eisenhandler R, et al. 1993 Growth hormone response in man to L-692,429, a novel non peptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab. 77:1393-1397.
7. Smith RG, Cheng K, Pong SS, Hickey G, Jacks T, Butler B, et al. 1993 A non-peptidyl GH secretagogue. Science. 260:1640-1643.
8. Jacks T, Hickey G, Judith F, et al. 1994 Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I. ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol. 143:399-406.
9. Chang CH, Rickes EL, Marsilio F, et al. 1995 Activity of a novel non peptidyl GH secretagogue, L-700,653, in swine. Endocrinology. 136:1065-1071.
10. Hickey GJ, Jacks T, Judith F, et al. 1994 Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles. Endocrinology 134:695-701.
11. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. 1990 Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 70:975-982.
12. Imbimbo BP, Mant T, Edward M, et al. 1994 Growth hormone releasing activity of hexarelin in humans: a dose-response study. Eur J Clin Pharmacol. 46:421-425.
13. Ghigo E, Arvat E, Gianotti L, et al. 1994 Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab. 78:693-698.
14. Korbonits M, Trainer PJ, Besser GM. 1995 The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clin Endocrinol (Oxf). 43:365-371.
15. Copinschi G, van Onderbergen A, L'hermite-Baleriaux M, et al. 1996 Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab. 81:2776-2782.
16. Codd EE, Shu AYL, Walker RF. 1989 Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology. 28:1139-1144.
17. Veeraragavan K, Sethumadhavan K, Bowers CY. 1992 Growth hormone-releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes. Life Sci. 50:1149-1155.
18. Pong SS, Chaung LYP, Dean DC, Nargunt RP, Patchett AA, Smith RG. 1996 Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol. 10:57-61.
19. Howard AD, Feighner SD, Cully DF, et al. 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273:974-977.
20. Mallo F, Alvarez CV, Benitez L, Burguera B, Coya R, Casanueva FF. 1992 Regulation of His-dTRP-Ala-Trp-dPhe-Lys-NH2 (GHRP6)-induced GH secretion in the rat. Neuroendocrinology. 57:247-251.
21. Hickey GJ, Drisko J, Faidley T, et al. 1996 Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J Endocrinol. 148:371-380.
22. Bowers CY, Momany FA, Reynolds GA, Hong A. 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545.
23. Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K. 1984 Conformational energy studies and in vitro and in vivo activity data on active GH releasing peptides. Endocrinology 114:1531-1536.
24. Orth DN. 1992 Corticotropin-releasing hormone in humans. Endocr Rev. 13:164-191.
25. Arvat E, Maccagno B, Gianotti L, et al. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man. J Endocrinol Invest. 20:122-127.
26. Chapman IM, Bach MA, van Cauter E, et al. 1996 Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 81:4249-4257.
27. Leal Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF. 1994 Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clin Endocrinol (Oxf). 41:649-654.
28. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP. 1994 Suppressed spontaneous and stimulated growth hormone secretion in Cushing's disease before and after surgical cure. J Clin Endocrinol Metab. 78:131-137.
29. Giustina A, Bossoni S, Bodini C, et al. 1991 Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease. Horm Res. 35:99-103.
30. Procopio M, Invitti C, Maccario M, et al. 1995 Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. Int J Obesity. 19:108-112.
31. Goth MI, Lyons CE, Canny BY, Thorner MO. 1992 Pituitary adenilate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology. 130:939-944.
32. Fairhall KM, Mynett A, Robinson ICAF. 1995 Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol. 144:555-560.
33. Dieguez C, Mallo F, Senaris R, et al. 1996 Role of glucocorticoids in the neuroregulation of growth hormone secretion. J Pediatr Endocrinol Metab. 9:255-260.
34. Cordido F, Peino R, Penalva A, Alvarez CV, Casanueva FF, Dieguez C. 1996 Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J Clin Endocrinol Metab. 81:914-918.
35. Maccario M, Arvat E, Procopio M, et al. 1995 Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. Metabolism. 44:134-138.